220O RATIONALE-309: Effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)

Y Yang,J Pan,N Chen,Y Wu,S Leaw,F Bai,Y Wang,N Zhao,B Tang,G Barnes

doi:10.1016/j.annonc.2022.10.255

220O RATIONALE-309: Effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)

Y Yang, J Pan + Show 8 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.255

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Sun Yat-sen University Cancer Center, Fujian Medical University, West China Hospital of Sichuan University

#Gemcitabine And Cisplatin #Health-related Quality Of Life + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In RATIONALE-309 (NCT03924986), tislelizumab with gemcitabine and cisplatin (GP) improved progression-free survival, objective response rate, and duration of response compared to placebo +GP in patients receiving first-line treatment for R/M NPC. This study evaluated HRQoL in the intent-to-treat (ITT) population and post-hoc analysis examined HRQoL in patients with liver metastases (LM) subgroup, a negative prognostic factor of overall and cancer-specific survival in patients with NPC.

Full Text